Navigation Links
In the real life setting, boosted REYATAZ proves as effective in women living with HIV as men
Date:7/20/2011

(ROME, 20 July 2011) Bristol-Myers Squibb Company announced results from a long-term, retrospective, European cohort study, which included 1,294 antiretroviral (ARV)-experienced patients (336 female and 958 male) from Germany, France and Sweden, that were presented today at the Sixth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011).

In a gender-specific sub-analysis, boosted REYATAZ (atazanavir sulphate) (ATV/ritonavir)-based regimens demonstrated no difference in time to virologic failure in women compared to men over a follow-up period of up to five years.2

Approximately 30 years into the AIDS epidemic, nearly 16 million women are living with HIV, and most of them are of childbearing age.3 HIV has become the leading cause of disease and death among women of reproductive age worldwide.4 In Europe, women account for 35% of new HIV diagnoses.1 However, data on efficacy, safety and tolerability on antiretrovirals (ARVs) in women are limited, as they are under-represented in clinical trials.5

"More clinical data, especially long-term data, evaluating ARV response in women with HIV are needed to improve their management; in this way, the results presented today give us as physicians relevant and valuable information," said Prof. Dr Norbert H. Brockmeyer, Germany.

This retrospective, observational study collected data from three European databases (France DatAids; Germany KompNet; Sweden InfCare). All participants were ARV-treatment experienced patients; 336 female (median age of 40 years) and 958 male (median age of 44 years).2 The present sub-analysis evaluated the effect of gender on long-term outcomes of ATV/r-based regimens.

The results revealed no gender-based differences in time to virological failure, defined as two consecutive HIV RNA ≥ 50 c/mL or one HIV RNA ≥ 50 c/mL followed by discontinuation. After three years of follow-up, the probability of not having virological failure was 59% for women (95% CI 52-65%) and 63% for men (95% CI 59-67%). As seen in several other recent studies,6,7 female gender was associated with increased risk of treatment discontinuation but not with a significantly higher risk of virologic failure.2

The cohort results also showed that REYATAZ/ritonavir is a well-tolerated therapeutic option for treatment-experienced patients of either gender.2 Overall, the safety profile was comparable among men and women and similar to that previously described in clinical trials. Among women, diarrhoea was reported in 2%, nausea in < 1%, jaundice in < 1%, lipodystrophy in 5% and bone density abnormalities in < 1% of the cases.2

The results reported in this gender-specific sub-analysis are consistent with those previously reported in clinical trials (i.e CASTLE study gender analysis) in which boosted REYATAZ showed durable viral suppression and favourable safety and tolerability profiles, irrespective of gender.


'/>"/>

Contact: Joanna Ritter
33-015-883-6509
TogoRun
Source:Eurekalert

Related medicine news :

1. Animal-assisted therapy decreases patient anxiety in pre-MRI setting, study suggests
2. Hispanic Aesthetics Boosted by Dr. Mark Berman, President of the American Academy of Cosmetic Surgery
3. Sexual, Urinary Health Boosted in Exercisers, Nonsmokers
4. Study shows durable viral suppression of boosted REYATAZ in treatment-experienced HIV patients
5. A New Website Series Improves Appearance and Health City by City
6. Kaiser Permanente Approves $170 Million in Community Benefit Grants in 2009
7. Behavioral therapy improves sleep and lives of patients with pain
8. New Successful Treatment Improves Walking Post Stroke
9. Short on specialized intensive care physicians, team-based approach improves ICU outcomes
10. Belief in a caring god improves response to medical treatment for depression
11. Combined drug therapy to treat TB and HIV significantly improves survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... 06, 2016 , ... From May 4 to 6, EarQ and ... opportunity to learn more about Signia’s technology and the successful business and marketing techniques ... priority to see practices succeed in this highly competitive industry,” said Ed Keller, president ...
(Date:5/6/2016)... Arizona (PRWEB) , ... May 06, 2016 , ... ... moved domains to Sleepopolis.com . , Since launching in September, 2014 Sleepopolis ... research and testing areas, which now include pillows, sheets, mattress toppers, bed frames, ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... online provider of career-focused education and corporate training, and the National Military Family ... to announce Maritza Aquino as the second full-tuition scholarship recipient of 2016. ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, Inc. ... Cross BlueShield and Former Principal Deputy Administrator at Centers for Medicare and Medicaid ... Steve Ondra, MD, Chief Medical Officer at Health Care Service Corporation (Blue Cross ...
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono Inc. , ... a development collaboration with the Australian critical medicine company, Phebra Pty Ltd. ... , LAI medicines can offer improved therapeutic benefits over oral formulations, including better ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research and Markets has announced ... in the USA"  report to their offering.  ,     (Logo: ... the current Positron Emission Tomography (PET) scanner and cyclotron ... market. Along with the current known number of PET ... , the report also contains a detailed breakdown of ...
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocytopenia Market and ... to their offering.       ... ,The latest research Europe Thrombocytopenia Market ... provides comprehensive insights into Thrombocytopenia pipeline ...
(Date:5/4/2016)... Conn., May 4, 2016  Compass Diversified Holdings (NYSE: ... "Company"), an owner of leading middle market businesses, announced ... ended March 31, 2016. First Quarter 2016 ... and Reinvestment ("CAD" or "Cash Flow") of $13.6 million ... net loss of $15.0 million for the first quarter ...
Breaking Medicine Technology: